FIELD: chemistry.
SUBSTANCE: present invention relates to chemical-pharmaceutical industry and medicine, particularly treating demyelinating diseases. Disclosed is a pharmaceutical composition in solid dosage form, having therapeutic effect on demyelinating disease, particularly multiple sclerosis, containing as an active substance biotin and target additives in certain proportions.
EFFECT: composition is stable during storage for not less than 2,5 and has high bioavailability.
9 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING MULTIPLE SCLEROSIS (VERSIONS) | 2011 |
|
RU2471482C1 |
| COMPOSITION FOR TREATING MULTIPLE SCLEROSIS (VERSIONS) | 2012 |
|
RU2493845C1 |
| METHOD OF PRODUCING DALFAMPRIDIN TABLETS WITH PROLONGED ACTION | 2015 |
|
RU2607655C1 |
| COMPOSITION FOR TREATING DISTURBED INNERVATION (VERSIONS) | 2013 |
|
RU2536269C1 |
| BIOTIN TABLETS WITH DELAYED RELEASE AND METHOD FOR OBTAINING THEREOF | 2016 |
|
RU2638803C2 |
| PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATING DEMYELINIATING DISEASES | 2013 |
|
RU2530626C1 |
| PHARMACEUTICAL COMPOSITION OF PROLONGED ACTION FOR CORRECTION OF PSYCHOSOMATIC MANIFESTATIONS | 2009 |
|
RU2424807C2 |
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
| PHARMACEUTICAL COMPOSITION IN SOLID FORM WITH ANALGESIC ACTIVITY | 2013 |
|
RU2545861C1 |
| ENCAPSULATED DOSAGE FORM, CONTAINING MONTELUKAST AND LEVOCETIRIZINE | 2012 |
|
RU2606857C2 |
